Patents by Inventor David K. McClintock

David K. McClintock has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Efficacious vaccines against Bordetella pertussis comprising a combination of individually purified pertussis antigens
    Patent number: 5897867
    Abstract: This invention is directed to a vaccine for the prevention of disease caused by Bordetella pertussis which comprises the pertussis antigens filamentous hemagglutinin, detoxified lymphocytosis promoting factor and a 69 kilodalton outer membrane protein, where said antigens are individually purified prior to being combined to form the vaccine. The invention is further directed to pertussis vaccines where the antigens are combined in any ratio, including ratios not possible in whole cell or co-purified acellular pertussis vaccines. The pertussis antigens may be further combined with other individually purified pertussis antigens, pertussis structural components, adjuvants, stabilizers and non-pertussis vaccine components.
    Type: Grant
    Filed: May 22, 1995
    Date of Patent: April 27, 1999
    Assignee: American Cyanamid Company
    Inventors: Thomas G. Eckhardt, John W. Gotto, David K. McClintock, Jane V. Scott
  • Efficacious vaccines against Bordetella pertussis comprising a combination of individually purified pertussis antigens
    Patent number: 5895655
    Abstract: This invention is directed to a vaccine for the prevention of disease caused by Bordetella pertussis which comprises the pertussis antigens filamentous hemagglutinin, detoxified lymphocytosis promoting factor and a 69 kilodalton outer membrane protein, where said antigens are individually purified prior to being combined to form the vaccine. The invention is further directed to pertussis vaccines where the antigens are combined in any ratio, including ratios not possible in whole cell or co-purified acellular pertussis vaccines. The pertussis antigens may be further combined with other individually purified pertussis antigens, pertussis structural components, adjuvants, stabilizers and non-pertussis vaccine components.
    Type: Grant
    Filed: May 22, 1995
    Date of Patent: April 20, 1999
    Assignee: American Cyanamid Company
    Inventors: Thomas G. Eckhardt, John W. Gotto, David K. McClintock, Jane V. Scott
  • Efficacious vaccines against Bordetella pertussis comprising a combination of individually purified pertussis antigens
    Patent number: 5885587
    Abstract: This invention is directed to a vaccine for the prevention of disease caused by Bordetella pertussis which comprises the pertussis antigens filamentous hemagglutinin, detoxified lymphocytosis promoting factor and a 69 kilodalton outer membrane protein, where said antigens are individually purified prior to being combined to form the vaccine. The invention is further directed to pertussis vaccines where the antigens are combined in any ratio, including ratios not possible in whole cell or co-purified acellular pertussis vaccines. The pertussis antigens may be further combined with other individually purified pertussis antigens, pertussis structural components, adjuvants, stabilizers and non-pertussis vaccine components.
    Type: Grant
    Filed: May 22, 1995
    Date of Patent: March 23, 1999
    Assignee: American Cyanamid Company
    Inventors: Thomas G. Eckhardt, John W. Gotto, David K. McClintock, Jane V. Scott
  • Efficacious vaccines against bordetella pertussis comprising a combination of individually purified pertussis antigens
    Patent number: 5885586
    Abstract: This invention is directed to a vaccine for the prevention of disease caused by Bordetella pertussis which comprises the pertussis antigens filamentous hemagglutinin, detoxified lymphocytosis promoting factor and a 69 kilodalton outer membrane protein, where said antigens are individually purified prior to being combined to form the vaccine. The invention is further directed to pertussis vaccines where the antigens are combined in any ratio, including ratios not possible in whole cell or co-purified acellular pertussis vaccines. The pertussis antigens may be further combined with other individually purified pertussis antigens, pertussis structural components, adjuvants, stabilizers and non-pertussis vaccine components.
    Type: Grant
    Filed: May 22, 1995
    Date of Patent: March 23, 1999
    Assignee: American Cyanamid Company
    Inventors: Thomas G. Eckhardt, John W. Gotto, David K. McClintock, Jane V. Scott